Covovax

The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.

Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute's Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday.

The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in the 7-11 age group on June 28, 2022, subject to certain conditions.

China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.

Serum Institute of India has written to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults, official sources said on Wednesday.

The Serum Institute of India is working to market its two key vaccines for Covid -- Covovax and Covishield -- in China, which is seeing a resurgence of the pandemic.

An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for adults, Press Trust of India reported.

Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus.

The Drugs Controller General of India (DCGI) on Tuesday approved Serum Institute's COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions, official sources said.

Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.

Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.

National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.

Serum Institute's Adar Poonawalla said Covovax is the first vaccine made in India to be sold in Europe.

Mr Poonawala told NDTV that Covishield will cost Rs 600 plus taxes (same as before) and Covovax, once approved as a booster, will be available for Rs.900 plus taxes.

The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.

The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.

Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute's Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday.

The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in the 7-11 age group on June 28, 2022, subject to certain conditions.

China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.

Serum Institute of India has written to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults, official sources said on Wednesday.

The Serum Institute of India is working to market its two key vaccines for Covid -- Covovax and Covishield -- in China, which is seeing a resurgence of the pandemic.

An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for adults, Press Trust of India reported.

Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus.

The Drugs Controller General of India (DCGI) on Tuesday approved Serum Institute's COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions, official sources said.

Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.

Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.

National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.

Serum Institute's Adar Poonawalla said Covovax is the first vaccine made in India to be sold in Europe.

Mr Poonawala told NDTV that Covishield will cost Rs 600 plus taxes (same as before) and Covovax, once approved as a booster, will be available for Rs.900 plus taxes.

The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.